Literature DB >> 22963673

Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients.

S Buhner1, Q Li, T Berger, S Vignali, G Barbara, R De Giorgio, V Stanghellini, M Schemann.   

Abstract

BACKGROUND: We previously showed that colonic mucosal biopsy supernatants from patients with irritable bowel syndrome (IBS) activate neurons of the human submucous plexus, an area with densely packed immune cells. Based on the concept that mucosa-nerve signaling is altered in IBS, we tested in this study whether the nerve sensitizing effect of IBS mucosal biopsy supernatants is more prominent in the submucous than myenteric plexus.
METHODS: Fast neuroimaging with the voltage-sensitive dye Di-8-ANEPPS was used to record activity of guinea-pig submucous and myenteric neurons after application of constipation (C)- and diarrhea (D)-IBS supernatants (three each) and four supernatants from healthy control subjects. Results are based on recordings from 4731 neurons. KEY
RESULTS: Control supernatants did not evoke significant responses in submucous or myenteric neurons. In contrast, all IBS supernatants evoked a significant spike discharge (median 3.6 Hz) in 46% of submucous neurons. This activation was significantly stronger than in the myenteric plexus where even twice the amount of supernatants evoked a lower spike frequency (median 2.1Hz) in only 8.5% of neurons. Pharmacological studies revealed serotonin, histamine, and proteases as components mediating neuronal activation. Individual application of these components revealed that only serotonin evoked a significantly stronger activation of submucous compared with myenteric neurons. CONCLUSIONS & INFERENCES: Direct neuronal activation by IBS mucosal biopsy supernatants is primarily a feature of submucous rather than myenteric neurons. This is associated with a stronger excitation of submucous neurons by serotonin. The plexus-specific effects support the concept that altered mucosa-nerve signaling underlies disturbances in IBS.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22963673     DOI: 10.1111/nmo.12011

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  18 in total

1.  Modulation of enteric neurons by interleukin-6 and corticotropin-releasing factor contributes to visceral hypersensitivity and altered colonic motility in a rat model of irritable bowel syndrome.

Authors:  Maria M Buckley; Ken D O'Halloran; Mark G Rae; Timothy G Dinan; Dervla O'Malley
Journal:  J Physiol       Date:  2014-09-25       Impact factor: 5.182

Review 2.  Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.

Authors:  Lena Öhman; Hans Törnblom; Magnus Simrén
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-12-02       Impact factor: 46.802

3.  Gender-related differential effect of tachykinin NK2 receptor-mediated visceral hyperalgesia in guinea pig colon.

Authors:  F Bellucci; L Buéno; R Bugianesi; A Crea; V D'Aranno; S Meini; P Santicioli; M Tramontana; C A Maggi
Journal:  Br J Pharmacol       Date:  2016-03-07       Impact factor: 8.739

Review 4.  Role of enteric neurotransmission in host defense and protection of the gastrointestinal tract.

Authors:  Keith A Sharkey; Tor C Savidge
Journal:  Auton Neurosci       Date:  2013-12-22       Impact factor: 3.145

Review 5.  The mucosal immune system: master regulator of bidirectional gut-brain communications.

Authors:  Nick Powell; Marjorie M Walker; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-01-18       Impact factor: 46.802

6.  Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity.

Authors:  John P Russell; Ehsan Mohammadi; Casey O Ligon; Anthony C Johnson; Michael D Gershon; Meenakshi Rao; Yuhong Shen; Chi-Chung Chan; Hilary S Eidam; Michael P DeMartino; Mui Cheung; Allen I Oliff; Sanjay Kumar; Beverley Greenwood-Van Meerveld
Journal:  J Pharmacol Exp Ther       Date:  2018-11-09       Impact factor: 4.030

7.  Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS.

Authors:  Hilary Schenck Eidam; John Russell; Kaushik Raha; Michael DeMartino; Donghui Qin; Huiping Amy Guan; Zhiliu Zhang; Gong Zhen; Haiyu Yu; Chengde Wu; Yan Pan; Gerard Joberty; Nico Zinn; Sylvie Laquerre; Sharon Robinson; Angela White; Amanda Giddings; Ehsan Mohammadi; Beverly Greenwood-Van Meerveld; Allen Oliff; Sanjay Kumar; Mui Cheung
Journal:  ACS Med Chem Lett       Date:  2018-05-24       Impact factor: 4.345

8.  Mast cell expression of the serotonin1A receptor in guinea pig and human intestine.

Authors:  Guo-Du Wang; Xi-Yu Wang; Fei Zou; Meihua Qu; Sumei Liu; Guijun Fei; Yun Xia; Bradley J Needleman; Dean J Mikami; Jackie D Wood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-21       Impact factor: 4.052

Review 9.  The enteric nervous system in gastrointestinal disease etiology.

Authors:  Amy Marie Holland; Ana Carina Bon-Frauches; Daniel Keszthelyi; Veerle Melotte; Werend Boesmans
Journal:  Cell Mol Life Sci       Date:  2021-03-26       Impact factor: 9.261

10.  Drug development for the irritable bowel syndrome: current challenges and future perspectives.

Authors:  Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.